Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Alpha Cognition Inc. is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are located in 2 distinct art units, which indicates that while there is some technical concentration, the applications are being reviewed by more than 1 specialized group. This spread across 2 distinct art units suggests that the company's biotechnology research spans multiple sub-specialties within the pharmaceutical sector. The 3 pending office actions show a consistent level of engagement with the patent office. This structure allows the company to receive feedback from multiple reviewers while remaining within a limited number of technical disciplines.
GONZALEZ, LUISALBERTO is the busiest examiner for the portfolio, currently overseeing 1 pending office action. The company's workload is evenly split among 3 distinct examiners, with each individual responsible for exactly 1 pending matter. This 1 to 1 ratio of 3 pending office actions to 3 distinct examiners ensures that the company receives a unique perspective on each of its applications. By interacting with 3 distinct examiners across 2 distinct art units, the company avoids concentration risk and benefits from a range of technical feedback on its pharmaceutical claims. No single examiner has a dominant influence over the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560636 | SELF-PRESERVING COMPOSITIONS AND MULTI-USE DISPENSERS FOR ADMINISTERING ALPHA-1062 | HAVLIN, ROBERT H | 22d |
| 18562241 | GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE | CHERNYSHEV, OLGA N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560636 | SELF-PRESERVING COMPOSITIONS AND MULTI-USE DISPENSERS FOR ADMINISTERING ALPHA-1062 | HAVLIN, ROBERT H | 22d |
| 18965776 | SOLID FORMS OF ALPHA-1062 GLUCONATE | GONZALEZ, LUISALBERTO | — |
| 18562241 | GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18965776 | SOLID FORMS OF ALPHA-1062 GLUCONATE | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18562241 | GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE | CHERNYSHEV, OLGA N | — | §101§102§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18560636 | SELF-PRESERVING COMPOSITIONS AND MULTI-USE DISPENSERS FOR ADMINISTERING ALPHA-1062 | HAVLIN, ROBERT H | 1626 | §103§112Other | Final Rejection | 22d | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial